get a key
steadybase-$ company TOI
account_id none on file
legal_name Starling Oncology, Inc.
ticker TOI
cik 1799191
domain theoncologyinstitute.com
entry_point_account_id none on file
name The Oncology Institute Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 5 executives 2 family 0
why_nownone on file
callsnone on file
filings
As a percentage of revenue, SG&A decreased 390 basis points for the three months ended June 30, 2026 as compared to the same period in the prior year which reflected the operating leverage built into the model as the Company's continues to scale, along with cost discipline.

filing / Aug 6, 2026 / receipt

(4) Infrastructure and workforce costs were primarily comprised of recruiting expenses to build out corporate infrastructure of $305 and $150, severance expenses resulting from cost rationalization programs of $15 and $49, stop-loss contract timing of approximately $0 and $1,099, and reversal of settlements of $165 and $487 during the three months ended June 30, 2026 and 2025, respectively.

filing / Aug 6, 2026 / receipt

(4) Infrastructure and workforce costs were primarily comprised of recruiting expenses to build out corporate infrastructure of $476 and $150, severance expenses resulting from cost rationalization programs of $257 and $49, stop-loss contract timing of approximately $1 and $1,099, and legal costs related to infrastructure build out and settlements of $172 and $487, partially offset by EOM/CMS performance period non-r

filing / Aug 6, 2026 / receipt

(4) Infrastructure and workforce costs were comprised of recruiting expenses to build out corporate infrastructure of $169 and $277, severance expenses resulting from cost rationalization programs of $242 and $140, stop-loss contract timing of approximately $1 and $0, EOM/CMS performance period non-recurring addback of $818 and $0, and non-recurring legal fees related to infrastructure build out and settlements of $3

filing / May 7, 2026 / receipt

If the Company cannot generate or obtain needed funds, it might be forced to make substantial reductions in its operating and capital expenses or pursue restructuring plans, which could adversely affect its business operations and ability to execute its current business strategy.

filing / May 7, 2026 / receipt

executives
Daniel Virnich Chief Executive Officer - receipt
Jeremy N. Castle Chief Operations Officer - receipt
familynone on file
upcomingnone on file
changes
2023-09-06 Chief Operations Officer, appointed sec_8k
2023-06-14 Chief Executive Officer, appointed sec_8k
2023-06-12 Chief Executive Officer, appointed sec_8k
2022-03-07 President, appointed sec_8k
mcp_package_hint
steadybase-$